Evaluation of derivatives of 3-(2-oxo-1-pyrrolidine) hexahydro-1H-azepine-2-one as dermal penetration enhancers: side chain length variation and molecular modeling

Wilkes, 1973, The biochemical properties of skin, Crit. Rev. Bioeng., 1, 453 Millington, 1983 Bodde, 1989, The skin compliance of transdermal drug delivery systems, Crit. Rev. Ther. Drug Carrier Syst., 6, 87 Elias, 1996, The stratum corneum revisited, J. Dermatol., 23, 756, 10.1111/j.1346-8138.1996.tb02698.x Holbrook, 1993, The structure and development of skin, 97 Ghosh, 1993, Methods of enhancement of transdermal drug delivery: Part IIA. Chemical permeation enhancers, Pharm. Tech., April, 62 Ghosh, 1993, Methods of enhancement of transdermal drug delivery: Part IIB. Chemical permeation enhancers, Pharm. Tech., May, 68 Barry, 1987, Mode of action of penetration enhancers in human skin, J. Control. Release, 6, 85, 10.1016/0168-3659(87)90066-6 Walters, 1989, Penetration enhancers and their use in transdermal therapeutic systems, 197 Stoughton, 1982, Enhanced percutaneous penetration with 1-dodecylazacycloheptan-2-one, Arch. Dermatol., 118, 474, 10.1001/archderm.118.7.474 Sugibayashi, 1985, Effect of the absorption enhancer, Azone®, on the transport of 5-fluorouracil across hairless rat skin, J. Pharm. Pharmacol., 37, 578, 10.1111/j.2042-7158.1985.tb03073.x Hadgraft, 1993, Azone®, mechanisms of action and clinical effect, 175 Williams, 1992, Skin absorption enhancers, Crit. Rev. Ther. Drug Carrier Syst., 9, 305 Barry, 1985, Optimizing percutaneous absorption, 489 Okamoto, 1988, Structure-activity relationship of 1-alkyl- or 1-alkenylazacycloalkanone derivatives as percutaneous penetration enhancers, J. Pharm. Sci., 77, 418, 10.1002/jps.2600770513 Michniak, 1993, In vitro evaluation of a series of Azone® analogs as dermal penetration enhancers, Int. J. Pharm., 91, 85, 10.1016/0378-5173(93)90424-E Sasaki, 1990, Enhancing effect of pyrrolidone derivatives on transdermal drug delivery. II. Effect of application concentration and pre-treatment of enhancer, Int. J. Pharm., 60, 177, 10.1016/0378-5173(90)90070-K Pilgram, 2000, The effect of two Azones on the lateral lipid organiation of human straum corneum and its permeability, Pharm. Res., 17, 796, 10.1023/A:1007547906856 Michniak, 1993, Facilitated transport of two model steroids by esters and amides of clofibric acid, J. Pharm. Sci., 82, 214, 10.1002/jps.2600820221 Michniak, 1996, Synthesis and in vitro transdermal penetration enhancing activity of lactam N-acetic acid esters, J. Pharm. Sci., 85, 150, 10.1021/js950331n Hoogstraate, 1991, Kinetics, ultrastructural aspects and molecular modeling of transdermal peptide flux enhancement by N-alkyl azacyclo-heptanones, Int. J. Pharm., 76, 37, 10.1016/0378-5173(91)90341-K Sasaki, 1991, Enhancing effect of pyrrolidone derivatives on transdermal penetration of 5-fluorouracil, triamcinolone acetonide, indomethacin, and flubiprofen, J. Pharm. Sci., 80, 533, 10.1002/jps.2600800606 Yoneto, 1995, Mechanistic studies of the 1-alkyl-2-pyrrolidones as skin permeation enhancers, J. Pharm. Sci., 84, 312, 10.1002/jps.2600840310 Goodman, 1988, Action of penetration enhancers on human skin as assessed by the permeation of model drugs 5-fluorouracil and estradiol. I. Infinite dose technique, J. Invest. Dermatol., 91, 323, 10.1111/1523-1747.ep12475655 Bouwstra, 1992, The influence of alkyl-Azone® s on the ordering of the lamellae in human stratum corneum, Int. J. Pharm., 79, 141, 10.1016/0378-5173(92)90105-B Aungst, 1986, Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides, and amides, Int. J. Pharm., 33, 225, 10.1016/0378-5173(86)90057-8 Quan, 1990, Enhancement effect of piperidone derivatives on the percutaneous absorption of indomethacin, Drug Des. Deliv., 6, 61 Cooper, 1985, Effect of fatty acids and alcohols on the penetration of acyclovir across human skin in vitro, J. Pharm. Sci., 74, 688, 10.1002/jps.2600740623 Hori, 1991, Enhancement of proparanol hydrochloride and diazepam skin absorption in vitro: effect of enhancer lipophilicity, J. Pharm. Sci., 80, 32, 10.1002/jps.2600800109 Scheuplein, 1967, Mechanism of percutaneous absorption II: transient diffusion and the relative importance of various routes of skin penetration, J. Invest. Dermatol., 48, 79, 10.1038/jid.1967.11 Bronaugh, 1983, Dermatotoxicology, 117 Higuchi, 1987, Prodrugs in transdermal delivery, 43 Ogiso, 1995, Effects of enhancers on transdermal penetration of indomethacin and urea, and relationship between penetration parameters and enhancement factors, J. Pharm. Sci., 84, 482, 10.1002/jps.2600840418 Williams, 1991, Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement, Pharm. Res., 8, 17, 10.1023/A:1015813803205 Takayama, 1993, Terpenes as percutaneous absorption promoters, S.T. P. Pharm. Sci., 183, 25 Hadgraft, 1996, Mechanisms of action of skin penetration enhancer/retarders: Azone® and analogues, Int. J. Pharm., 141, 17, 10.1016/0378-5173(96)04609-1 Bodde, 1989, Visualization of percutaneous transport and its enhancement, 8 Brian, 1993, Molecular modeling of skin permeation enhancement by chemical agents, 389 Atkins, 1994